Physician

Susannah Parker Friemel, M.D.

According to 2025 Medicare claims, Susannah Friemel, M.D. (NPI: 1356352116) practices internal medicine in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Scott, IA. This provider's primary affiliated billing organization is IOWA CANCER SPECIALISTS, P.C. (NPI: 1891803011; TIN: 061666841) and primary practice location at 52807-2707. Friemel is affiliated with the Genesis Accountable Care Organization, LLC. (ACO ID: A4799), participating under the MSSP model.

Friemel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 466 traditional Medicare patients, billed 351,904 HCPCS/CPT codes, and received $2,274,624 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,368 prescription claims across 287 beneficiaries totaling $8,152,307 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 22 claims. Open Payments data shows 72 records totaling $1,356. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,013,081 to $2,274,624. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,013,056 to $8,152,307. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	266	84,662	$1,013,081
2016	290	125,765	$831,148
2017	359	150,744	$1,038,357
2018	699	227,375	$2,492,168
2019	800	374,338	$3,968,877
2020	576	289,129	$3,383,147
2021	457	280,604	$3,241,321
2022	399	227,379	$3,243,939
2023	381	278,349	$2,652,434
2024	466	351,904	$2,274,624

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	132	1,129	$1,013,056
2016	150	1,202	$1,215,175
2017	149	1,146	$1,166,677
2018	285	1,749	$2,443,869
2019	355	2,573	$5,516,271
2020	301	2,438	$5,462,736
2021	303	2,263	$4,856,200
2022	285	2,096	$5,964,410
2023	277	2,009	$6,673,785
2024	287	2,368	$8,152,307

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	38	$1,283
2016	N/R	120	$37,504
2017	N/R	131	$20,738
2018	N/R	55	$2,297
2019	14	84	$6,153
2020	13	190	$9,925
2021	N/R	199	$10,320
2022	13	152	$8,539
2023	13	43	$3,431
2024	N/R	22	$955

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	285	688	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	196	230	$61
80053	Blood test, comprehensive group of blood chemicals	128	470	$10
36415	Insertion of needle into vein for collection of blood sample	160	280	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	334	1,173	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	46	1,380	$760,332
Ayvakit	Avapritinib	17	510	$651,204
Reblozyl	Luspatercept-Aamt	41	863	$593,356
Kisqali	Ribociclib Succinate	32	882	$491,655
Somatuline Depot	Lanreotide Acetate	56	1,116	$485,930

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	11	$817
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	72	$1,356	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Susannah Parker Friemel, M.D.?

Tedicare shows public-source Medicare data for Susannah Parker Friemel, M.D. (NPI 1356352116), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Susannah Parker Friemel, M.D. have ACO affiliation data?

Susannah Parker Friemel, M.D. is shown with ACO affiliation data for Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799).

What billing organization is linked to Susannah Parker Friemel, M.D.?

Susannah Parker Friemel, M.D. is linked to IOWA CANCER SPECIALISTS, P.C. (billing NPI 1891803011) in the available physician profile data.

Does Susannah Parker Friemel, M.D. have Open Payments data?

Susannah Parker Friemel, M.D. has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.